Biotech startup Atai collects $125M
November 25, 2020- Share:
Munich-based Atai Life Sciences has raised a $125 million Series C, including $32 million of its 2020 convertible debt. Investors in the round include Apeiron Investment Group, Peter Thiel and Catalio Capital Management. Atai is developing psychoactive compounds to treat mental health disorders. It will use the capital to fund the clinical development of its treatments and expand its drug candidate pipeline.
- Share:
-
-
-
-